Skip to content

Cancers & treatments

News & evidence

Living with cancer

Learn & contribute

Loading

A public, cited, editable map of oncology: technologies, targets, products, companies, institutions, pathways, trials, pairings, roadmaps, and ideas. One page per object, with a plain-language TL;DR on every page.

Work in progress. Every fact on this site is being built and checked in the open and may be incomplete, out of date, or wrong. You must do your own research and verify anything here at its primary source before relying on it. Nothing on this site is medical advice; decisions belong with you and your clinicians.

OnCo is an information resource, not medical advice. Nothing here replaces a conversation with a qualified clinician. Never delay care because of something you read here; in an emergency, call your local emergency services. Terms of use

Explore
Tags
Search
Path finder
For me
Navigator
Biomarker matrix
Calculators
Interactions
Decision aids
irAE guide
Tumour board
Compare
Landscape grid
Rankings
Timeline
Query
Graph explorer
Saved
Body map

Cancers & treatments

News & evidence

Institutions & people

Institutions
Universities
Trial leadership
People
Heroes and heroines
Companies
Startups
Requests for startups
Investors
Company scorecards
Trial sponsors
Manufacturing map
Countries
India deep dive
China deep dive
Cases by country
Funding flows

Living with cancer

For me
The first 60 days
Appointment prep pack
Side effects
Symptom to test
Report reader
Survivorship planner
Second opinion
Financial help
Free in oncology
Paying for care in the US
NHS coverage
Paying for care in India
Coverage rankings
Cutting cancer care costs
Diet, exercise and lifestyle
Supportive care
Complementary and supportive approaches
Hair loss and regrowth
Heroes and heroines

Learn & contribute

Reading paths
About & methodology
Roadmap
Gaps to fill
Completeness
Review queue
Reviewer roster
Contributors
Idea votes
Teaching packs
Weekly issue
Suggest an edit
Open evaluation
Data dictionary
Build on OnCo
Open API
Open data
Open tools
Open source in oncology
GitHub

© 2026 OnCo. Code MIT. The data are free for individual and educational use with the attribution “Data from OnCo (onco.cc)”, under CC BY-NC 4.0. Commercial use must contact us to pay for the data. Commercial licences. Made with heart and soul by Jude Gomila .

About and methodology Corrections Open API Tags Terms of use Privacy policy GitHub

Loading

Home
Cancers
Anaplastic thyroid cancer
Data

Cancers·Anaplastic thyroid cancer

DataAnaplastic thyroid cancer

Back to the Anaplastic thyroid cancer hub →31 connected records

Every connected record, the notes, the JSON, Markdown and RDF twins, and where the record came from and when it was checked.

Overview What it is Finding it Treating it Evidence The science Where you are Living with it What is coming Data

Data

Related pages

31

Direct links plus the targets, companies, and technologies of this cancer's products.

Similar pages

not linked directly; found by shared links

Cancer
Epithelioid haemangioendothelioma
Shares Doxorubicin, Paclitaxel / nab-paclitaxel, IMRT / IGRT (modern external beam) and the tag subtype-page.
Cancer
Inflammatory breast cancer
Shares Doxorubicin, Paclitaxel / nab-paclitaxel, IMRT / IGRT (modern external beam), Pembrolizumab and the tag subtype-page.
Cancer
Uterine carcinosarcoma
Shares Lenvatinib, Paclitaxel / nab-paclitaxel, IMRT / IGRT (modern external beam), Pembrolizumab and the tag subtype-page.
Cancer
BRAF V600-mutant melanoma
Shares Dabrafenib, Trametinib, BRAF, Pembrolizumab and the tag subtype-page.
Cancer
Endometrial cancer with no specific molecular profile
Shares Lenvatinib, Paclitaxel / nab-paclitaxel, IMRT / IGRT (modern external beam), Pembrolizumab and the tag subtype-page.
Cancer
Low-grade serous ovarian cancer
Shares Trametinib, Paclitaxel / nab-paclitaxel and the tag subtype-page.
Cancer
Stage III melanoma (after surgery)
Shares Dabrafenib, Trametinib, BRAF, Pembrolizumab and the tag subtype-page.
Cancer
Angiosarcoma
Shares Doxorubicin, Paclitaxel / nab-paclitaxel, IMRT / IGRT (modern external beam) and the tag subtype-page.

technologies

8

Anti-angiogenic therapy Cardio-oncology Cytotoxic chemotherapy Early integrated palliative care Immune checkpoint inhibitors IMRT / IGRT (modern external beam)Palliative radiotherapy Small-molecule kinase inhibitors

targets

7

BRAF FGFR2 KIT MEK1/2 PD-1 RET VEGF / VEGFR

drugs

6

ApprovedSmall-molecule BRAF kinase inhibitor

Dabrafenib · Tafinlar

ApprovedCytotoxic chemotherapy (anthracycline)

Doxorubicin · Adriamycin

ApprovedSmall-molecule multi-kinase inhibitor (VEGFR, FGFR, PDGFR, RET, KIT)

Lenvatinib · Lenvima

ApprovedCytotoxic chemotherapy (taxane)

Paclitaxel / nab-paclitaxel · Taxol / Abraxane

ApprovedMonoclonal antibody (anti-PD-1)

Pembrolizumab · Keytruda / Keytruda Qlex (SC)

ApprovedSmall-molecule allosteric MEK1/2 inhibitor

Trametinib · Mekinist

companies

4

CSPC Pharmaceutical Group Eisai Merck & Co. (MSD)Novartis

people

2

Keith C. Bible Vivek Subbiah

key papers

3

2021 American Thyroid Association guidelines for management of patients with anaplastic thyroid cancer Dabrafenib and trametinib in BRAF V600E-mutant anaplastic thyroid cancer (ROAR)Overall survival in anaplastic thyroid carcinoma 2000 to 2019: impact of targeted therapy and neoadjuvant BRAF-MEK inhibition

biomarkers

1

BRAF V600E (and V600K)

Machine-readable versions

The same record for scripts and assistants; checked 2026-09-17. Data CC BY-NC 4.0, attribute “Data from OnCo (onco.cc)”.

JSON with neighbours Markdown context RDF Turtle Sections with routes and counts API root

Not yet reviewedNeeds expert (clinical) and patient advocate review. Review this page or see the review queue and roster.

Model panel commentary is coming to this page: machine commentary, not clinical review.

ProvenanceLast edited 2026-09-18 · Jude Gomila · Link cancer subtypes to their siblings and name parents i… · diff · file

Wikipedia

Anaplastic thyroid cancer

Sources & links

Wikipedia

Data

JSON · ·

Follow this page

Wrong or missing?

Propose a change with a source. Organisations can update their own records. Every suggestion is reviewed, safety-checked and validated before it goes live; nothing is edited directly.

Suggest an editDiscuss start a thread

Out of date?
How review works

Machine-readable versions of Anaplastic thyroid cancer

JSON record with neighbours
Markdown context for language models
RDF Turtle for this record (its triples, relations and owl:sameAs; the IRI of this record is https://onco.cc/cancers/anaplastic-thyroid-cancer/)
Section plan: the ten sections of this record with routes, anchors and counts
All cancers as JSON
RDF N-Triples for the whole corpus
Search index: id, kind, name, TL;DR and route for every record
OpenAPI 3.1 description
API root and meta.json
llms.txt

MCP server: npx -y onco-mcp, tools search, get_entity, list_kind, ask, context, compare. This record is get_entity or context with id anaplastic-thyroid-cancer.

WebMCP tools registered on this page: onco_search, onco_get_entity.